Sinovac Biotech Ltd (SVA) stock
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.47+0.00 (0.00%)
Close on Nov 19, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $261.98M, up 18.7% from the year before. Over ten years it grew 18.3% a year on average. The highest annual figure on record is $18.38B in fiscal 2021.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $261.98M | +18.7% |
| FY2024 | Dec 31, 2024 | $220.69M | -31.7% |
| FY2023 | Dec 31, 2023 | $323.32M | -60.3% |
| FY2022 | Dec 31, 2022 | $815.24M | -95.6% |
| FY2021 | Dec 31, 2021 | $18.38B | +4044.0% |
| FY2020 | Dec 31, 2020 | $443.44M | +107.6% |
| FY2019 | Dec 31, 2019 | $213.58M | +4.2% |
| FY2018 | Dec 31, 2018 | $204.93M | +33.0% |
| FY2017 | Dec 31, 2017 | $154.11M | +208.0% |
| FY2016 | Dec 31, 2016 | $50.04M | +2.1% |
| FY2015 | Dec 31, 2015 | $49.01M | +3.3% |
| FY2014 | Dec 31, 2014 | $47.46M | -7.4% |
| FY2013 | Dec 31, 2013 | $51.27M | +70.2% |
| FY2012 | Dec 31, 2012 | $30.12M | -15.7% |
| FY2011 | Dec 31, 2011 | $35.71M | +114.1% |
| FY2010 | Dec 31, 2010 | $16.68M | -74.0% |
| FY2009 | Dec 31, 2009 | $64.13M | – |
See a number that looks wrong?